Клинический разбор в общей медицине №09 2026
Университет Мута, Эль-Карак, Иордания
Kabdelsater@mutah.edu.jo
Аннотация
Введение. Остеоартроз (OA) – это наиболее распространенное заболевание опорно-двигательного аппарата и основная причина инвалидизации лиц пожилого возраста. ОА, который первоначально считали следствием механического износа, в настоящее время признан возрастным дегенеративным заболеванием, поражающим различные ткани. Такие процессы, как геномная нестабильность, митохондриальная дисфункция и старение клеток, играют важнейшую роль в развитии и прогрессировании заболевания.
Цель и методы. В настоящем обзоре обобщены данные о механизмах, связывающих биологическое старение с патогенезом ОА, оценены новые методы лечения, направленные на борьбу со старением. В ходе поиска в базах данных PubMed, Embase, Cochrane Central и Google Scholar в соответствии с протоколом PRISMA среди 360 просмотренных записей идентифицированы 86 подходящих клинических и доклинических исследований.
Результаты. С возрастом в хондроцитах накапливаются повреждения ДНК, укорачиваются теломеры, возникают метаболические нарушения, приводящие к старению и формированию провоспалительного SASP-фенотипа. Стареющие клетки хрящевой ткани, синовиальной оболочки, субхондральной кости и жировой ткани взаимодействуют через паракринную сигнализацию и внеклеточные везикулы, вызывая хроническое воспаление и деградацию матрикса. Данные доклинических исследований показывают, что вмешательства, предполагающие воздействие на главные признаки старения, а именно применение сенолитиков и сеноморфиков, активация аутофагии, восстановление НАД⁺, терапия стволовыми клетками и изменение образа жизни, могут снизить бремя старения и замедлить развитие структурных нарушений, однако данных исследований на человеке по-прежнему недостаточно.
Выводы. Взгляды на OA следует пересмотреть – это возрастное системное заболевание суставов, а не просто повреждение хряща. Терапия, воздействующая на механизмы старения клеток на ранних стадиях, обладает реальным потенциалом с точки зрения изменения течения заболевания, однако для успешного внедрения в клиническую практику потребуются адаптированные к возрасту клинические стратегии и отбор пациентов по результатам анализа биомаркеров.
Ключевые слова: остеоартроз, старение, геномная нестабильность, старение хондроцитов, SASP-фенотип.
Для цитирования: Халед А. Абдель-Сатер. Остеоартроз как возрастное заболевание, поражающее различные ткани: геномная нестабильность, старение клеток и новые геротерапевтические стратегии. Клинический разбор в общей медицине. 2026; 7 (9): 91–93. DOI: 10.47407/kr2026.7.9.00935
Introduction
Osteoarthritis (OA) is the most prevalent musculoskeletal disorder and a leading cause of disability worldwide, with a rapidly increasing burden in aging populations [1]. Although genetics, obesity, sex, and joint injury contribute to risk, aging remains the strongest and most consistent determinant of OA development [2]. Epidemiological and experimental data indicate that biological aging processes – rather than mechanical wear alone – are central to disease initiation and progression [1, 3]. Modern concepts now recognize OA as a multi-tissue disorder involving cartilage, synovium, subchondral bone, and periarticular structures, all of which undergo age-related dysfunction [4].
Current OA therapies are largely palliative, focusing on pain control and functional support, with no approved disease-modifying treatments [5, 6]. This therapeutic gap reflects an incomplete targeting of upstream mechanisms. The geroscience framework proposes that conserved aging pathways drive chronic diseases, including OA [7]. Among these, cellular senescence has emerged as a key mechanism: senescent joint cells acquire a pro-inflammatory SASP that promotes matrix degradation, chronic inflammation, and secondary senescence across tissues [7–9]. While transient senescence can be beneficial, its persistent accumulation in aging joints becomes pathogenic [10].
Recognition of OA as an aging-driven condition has stimulated interest in therapies that target fundamental aging processes, including senolytics, senomorphics, and metabolic modulators [11]. This review integrates current evidence across joint compartments to clarify how genomic instability and cellular senescence orchestrate OA pathogenesis and to evaluate emerging anti-aging strategies with true disease-modifying potential.
Methods
This review followed a structured search strategy to identify evidence on aging, cellular senescence, and OA. Peer-reviewed studies published up to 2025 were retrieved from PubMed, Scopus, Web of Science, and Google Scholar using keywords including “osteoarthritis”, “aging”, “senescence”, “chondrocytes”, “SASP”, “DNA damage” and “disease-modifying therapies.”
Included were English-language studies examining age-related mechanisms in OA, biomarkers of senescence in joint tissues, and preclinical or clinical interventions targeting aging pathways. Studies focused on non-OA disorders, non–peer-reviewed sources, or reports lacking experimental or clinical data were excluded.
Findings were synthesized across molecular, preclinical, and clinical evidence to define shared biological patterns and therapeutic opportunities. This approach emphasized the multi-tissue, aging-driven nature of OA and integrated mechanistic insights with translational relevance.
Aging and Genomic Instability in Chondrocytes
DNA damage and oxidative stress. Aging and OA chondrocytes show increased DNA lesions and impaired repair capacity [12, 13]. Reactive oxygen species (ROS) accelerate telomere erosion and mitochondrial dysfunction, linking oxidative stress to senescence and matrix failure [8, 14, 15]. Persistent DNA damage activates the DNA damage response (DDR), favoring p53–p21–p16–mediated senescence rather than apoptosis, thereby promoting chronic tissue dysfunction [16–18].
Signaling pathways and organellar stress. The IKKα–NF-κB axis modulates oxidative damage responses; its suppression enhances DNA repair and limits senescence, positioning it as a therapeutic target [19, 20]. Mitochondrial DNA damage and defective mitophagy amplify ROS production, creating a self-reinforcing cycle of genomic and metabolic stress [21, 22]. Parallel lysosomal and endoplasmic reticulum stress further compromise proteostasis and cartilage integrity [21, 23].
DNA damage-induced senescence. Genomic instability drives irreversible chondrocyte senescence and acquisition of a pro-inflammatory SASP. Experimental DNA damage reproduces OA-like senescence features and SASP activation [24]. Together, these mechanisms converge on persistent senescence as the central cellular outcome that reshapes the joint microenvironment [9, 14].
Cellular senescence in the osteoarthritis joint: a multi-tissue perspective
Cartilage. Senescent chondrocytes accumulate with age and disease severity and causally drive degeneration [25, 28]. Their SASP suppresses collagen II and aggrecan synthesis while inducing matrix metalloproteinases; mTOR signaling regulates this output [29, 30]. Paracrine IL-6 signaling and EV-mediated microRNA transfer propagate senescence to neighboring cells [31–34]. Mechanical overload triggers senescence via Piezo1-mediated calcium influx and nuclear envelope stress, integrating biomechanical risk with aging biology [35–37]. Metabolic redox imbalance, circadian disruption (BMAL1 loss), and impaired FOXO–SIRT–AMPK signaling further promote chondrocyte aging [37–45].
Synovium. Senescent synovial fibroblasts accumulate through hypoxia/reoxygenation and inflammatory signaling, releasing SASP factors that intensify synovitis and cartilage damage [19, 46, 47]. Immune surveillance declines with age, enabling persistence of senescent cells through decoy receptor–mediated immune evasion [48–51].
Infrapatellar fat pad. The fat pad acts as a local senescence hub, secreting pro-inflammatory extracellular vesicles that induce chondrocyte dysfunction, paralleling systemic adipose tissue aging mechanisms [52, 53].
Subchondral bone. Senescent osteoblasts, osteocytes, and mesenchymal stromal cells disrupt bone remodeling and repair capacity; their clearance prevents age-related bone loss and OA progression [32, 54]. Stem cell exhaustion and metabolic reprogramming further accelerate sclerosis and joint degeneration [54].
Integrated mechanisms. Mechanical stress, oxidative injury, and inflammation induce senescence across joint tissues [14]. Once established, SASP signaling and extracellular vesicles create a bystander effect that spreads dysfunction [19, 55]. This self-propagating cycle represents a maladaptive “remodeling activation” program that explains disease persistence and the limited success of single-target therapies [56].
Overall, cellular senescence unifies genomic instability, metabolic failure, immune dysregulation, and biomechanical stress into a coherent model of OA pathogenesis, providing a strong rationale for senotherapeutic strategies aimed at disease modification rather than symptom control.
Anti-aging therapeutic strategies targeting osteoarthritis
Senolytic and senomorphic therapies. Senolytics aim to eliminate senescent chondrocytes, whereas senomorphics suppress SASP without inducing cell death. Dasatinib plus quercetin clears senescent cells and partially restores anabolic markers, with dasatinib providing the dominant effect [57]. Fisetin reduces chondrocyte senescence through SIRT6 pathways and slows OA progression [58]. Navitoclax shows senolytic activity but is limited by toxicity and inconsistent benefits [59]. Senomorphics such as rapamycin, resveratrol, and metformin reduce SASP and enhance autophagy, though systemic adverse effects restrict translation [14, 60, 61]. Even intra-articular hyaluronic acid exhibits senomorphic actions via SIRT1 activation and oxidative stress reduction [62].
Clinical evidence remains limited. Trials often exclude very old patients, and UBX0101 failed to meet primary endpoints in OA [39, 63, 64]. Safety concerns include transient inflammation after senescent cell clearance and drug-specific toxicities such as myelosuppression with navitoclax and dasatinib [57, 60]. Glucosamine is being reconsidered as a potential geroprotective agent through AMPK activation and autophagy enhancement, with improved delivery systems proposed to increase efficacy [65, 66]. Immunotherapeutic approaches – including CAR-T cells targeting senescent markers – represent emerging alternatives to small-molecule senolytics [67, 68].
Autophagy activation and mTOR inhibition. Enhancing autophagy offers an integrative strategy to restore cellular resilience. mTOR inhibition with rapamycin preserves chondrocyte viability, reduces synovitis, and limits cartilage loss in experimental OA [30, 69]. Activation of AMPK further supports metabolic homeostasis and suppresses senescence-associated inflammation [70]. Regenerative approaches such as autologous chondrocyte implantation and mesenchymal stem cell (MSC) therapies provide structural repair potential, with platelet-rich plasma enhancing MSC expansion and chondrogenesis [14].
Metabolic, anti-inflammaging, and regenerative strategies. Restoring NAD⁺ levels using nicotinamide riboside or nicotinamide mononucleotide improves mitochondrial function and protects cartilage in aging models, offering disease-modifying potential [71, 72]. Targeting inflammaging with metformin or low-dose cytokine inhibition can reduce SASP activity, while microRNA modulation represents an additional regulatory approach [73–75]. MSC-based therapies–particularly exosome and secretome preparations–suppress inflammation, enhance autophagy, and reduce chondrocyte senescence [76, 77]. Short-term safety appears acceptable, but long-term efficacy and durability require further study [78, 79].
Lifestyle and nutritional modulation of aging pathways in osteoarthritis
Nutrition influences OA primarily by regulating core aging mechanisms. Caloric restriction and intermittent fasting reduce senescence burden, suppress SASP mediators, and activate AMPK–sirtuin pathways while inhibiting mTOR, thereby enhancing autophagy and mitochondrial quality control in chondrocytes [23, 32, 80]. Mediterranean-style diets similarly reduce inflammation and metabolic stress, converging on pathways that delay chondrocyte senescence [81]. Caloric restriction mimetics such as resveratrol, quercetin, curcumin, metformin, and rapamycin replicate these molecular effects by suppressing NF-κB signaling and limiting cartilage catabolism [63, 82].
Physical activity functions as a systemic anti-senescence intervention. Physiological mechanical loading promotes chondrocyte autophagy, improves metabolic efficiency, and reduces inflammatory signaling, while exercise-induced myokines such as irisin inhibit NF-κB and Wnt/β-catenin pathways, protecting cartilage and subchondral bone [83, 84]. Even modest levels of regular activity are sufficient to reduce disability and preserve function in older adults with OA [85].
Circadian rhythm alignment represents an additional modifiable regulator of joint aging. Disruption of clock genes, particularly BMAL1, impairs DNA repair and autophagy and accelerates senescence in cartilage [41, 86]. Lifestyle measures that maintain circadian integrity therefore offer a practical, non-pharmacologic strategy to counteract inflammaging and slow OA progression.
Limitations, future perspectives, and conclusions
OA is a heterogeneous, aging-driven condition encompassing multiple phenotypes shaped by joint site, metabolic status, mechanical loading, and inflammatory burden. These differences lead to distinct senescence profiles and SASP signatures, limiting the universal applicability of current anti-aging strategies and complicating therapeutic translation across OA subtypes.
Clinical advancement is further constrained by the predominance of preclinical evidence, which inadequately reflects the complexity of aged human joints, comorbidities, and lifelong biomechanical stress. Additional challenges include potential off-target effects of senotherapeutics, uncertain dosing and durability, and a lack of long-term, age-stratified human trials.
Future progress depends on defining OA subtypes based on senescence burden, developing robust biomarkers for patient stratification and monitoring, and testing combination therapies that target multiple aging hallmarks. Integrating geroscience with precision medicine offers a pathway to shift OA management from symptomatic relief toward mechanism-based, disease-modifying interventions that improve joint health across the aging lifespan.
Conflict of interests. The author declares that there is not conflict of interests.
Конфликт интересов. Автор заявляет об отсутствии конфликта интересов.
Список литературы доступен на сайте журнала https://klin-razbor.ru/
The list of references is available on the journal‘s website https://klin-razbor.ru/
Information about the author
Информация об авторе
Khaled A. Abdel-Sater – MD, Department of Dental and Medical Sciences, Faculty of Dentistry, Mutah University, Al-Karak, Jordan. E-mail: Kabdelsater@mutah.edu.jo;
ORCID: 0000-0001-9357-4983
Халед А. Абдель-Сатер – д-р медицины, каф. стоматологии и медицинских наук, стоматологический факультет, Университет Мута, Эль-Карак, Иордания.
E-mail: Kabdelsater@mutah.edu.jo; ORCID: 0000-0001-9357-4983
Received: 26.01.2026
Revised: 10.02.2026
Accepted: 26.02.2026
Поступила в редакцию: 26.01.2026
Поступила после рецензирования: 10.02.2026
Принята к публикации: 26.02.2026
Клинический разбор в общей медицине №09 2026
Osteoarthritis as an aging-driven multi-tissue disorder: genomic instability, cellular senescence, and emerging gerotherapeutic strategies
Номера страниц в выпуске:91-93
Abstract
Background. Osteoarthritis (OA) is the most common musculoskeletal disorder and a major cause of disability in older adults. Once considered primarily a consequence of mechanical wear, OA is now recognized as an aging-driven, multi-tissue degenerative disease. Processes such as genomic instability, mitochondrial dysfunction, and cellular senescence play central roles in disease initiation and progression.
Objective and methods. This review synthesizes mechanistic evidence linking biological aging to OA pathogenesis and evaluates emerging senescence-targeted therapies. A PRISMA-informed narrative search of PubMed, Embase, Cochrane Central, and Google Scholar identified 86 relevant clinical and preclinical studies from 360 screened records.
Results. Aging chondrocytes accumulate DNA damage, telomere shortening, and metabolic dysfunction, leading to persistent senescence and a pro-inflammatory SASP. Senescent cells across cartilage, synovium, subchondral bone, and adipose tissue interact via paracrine and extracellular vesicle signaling, driving chronic inflammation and matrix degradation. Preclinical data show that interventions targeting aging hallmarks – including senolytics, senomorphics, autophagy activation, NAD⁺ restoration, stem cell-based therapies, and lifestyle modification–can reduce senescence burden and slow structural decline, though human evidence remains limited.
Conclusion. OA should be reframed as an aging-mediated systemic joint disorder rather than isolated cartilage failure. Therapies addressing upstream mechanisms of cellular aging offer realistic potential for disease modification, but successful translation will require age-adapted clinical strategies and biomarker-guided patient selection.
Keywords: osteoarthritis, aging, genomic instability, chondrocyte senescence, SASP.
For citation: Khaled A. Abdel-Sater. Osteoarthritis as an aging-driven multi-tissue disorder: genomic instability, cellular senescence, and emerging gerotherapeutic strategies. Clinical review for general practice. 2026; 7 (9): 91–93 (In Russ.). DOI: 10.47407/kr2026.7.9.00935
Background. Osteoarthritis (OA) is the most common musculoskeletal disorder and a major cause of disability in older adults. Once considered primarily a consequence of mechanical wear, OA is now recognized as an aging-driven, multi-tissue degenerative disease. Processes such as genomic instability, mitochondrial dysfunction, and cellular senescence play central roles in disease initiation and progression.
Objective and methods. This review synthesizes mechanistic evidence linking biological aging to OA pathogenesis and evaluates emerging senescence-targeted therapies. A PRISMA-informed narrative search of PubMed, Embase, Cochrane Central, and Google Scholar identified 86 relevant clinical and preclinical studies from 360 screened records.
Results. Aging chondrocytes accumulate DNA damage, telomere shortening, and metabolic dysfunction, leading to persistent senescence and a pro-inflammatory SASP. Senescent cells across cartilage, synovium, subchondral bone, and adipose tissue interact via paracrine and extracellular vesicle signaling, driving chronic inflammation and matrix degradation. Preclinical data show that interventions targeting aging hallmarks – including senolytics, senomorphics, autophagy activation, NAD⁺ restoration, stem cell-based therapies, and lifestyle modification–can reduce senescence burden and slow structural decline, though human evidence remains limited.
Conclusion. OA should be reframed as an aging-mediated systemic joint disorder rather than isolated cartilage failure. Therapies addressing upstream mechanisms of cellular aging offer realistic potential for disease modification, but successful translation will require age-adapted clinical strategies and biomarker-guided patient selection.
Keywords: osteoarthritis, aging, genomic instability, chondrocyte senescence, SASP.
For citation: Khaled A. Abdel-Sater. Osteoarthritis as an aging-driven multi-tissue disorder: genomic instability, cellular senescence, and emerging gerotherapeutic strategies. Clinical review for general practice. 2026; 7 (9): 91–93 (In Russ.). DOI: 10.47407/kr2026.7.9.00935
Остеоартроз как возрастное заболевание, поражающее различные ткани: геномная нестабильность, старение клеток и новые геротерапевтические стратегии
Халед А. Абдель-СатерУниверситет Мута, Эль-Карак, Иордания
Kabdelsater@mutah.edu.jo
Аннотация
Введение. Остеоартроз (OA) – это наиболее распространенное заболевание опорно-двигательного аппарата и основная причина инвалидизации лиц пожилого возраста. ОА, который первоначально считали следствием механического износа, в настоящее время признан возрастным дегенеративным заболеванием, поражающим различные ткани. Такие процессы, как геномная нестабильность, митохондриальная дисфункция и старение клеток, играют важнейшую роль в развитии и прогрессировании заболевания.
Цель и методы. В настоящем обзоре обобщены данные о механизмах, связывающих биологическое старение с патогенезом ОА, оценены новые методы лечения, направленные на борьбу со старением. В ходе поиска в базах данных PubMed, Embase, Cochrane Central и Google Scholar в соответствии с протоколом PRISMA среди 360 просмотренных записей идентифицированы 86 подходящих клинических и доклинических исследований.
Результаты. С возрастом в хондроцитах накапливаются повреждения ДНК, укорачиваются теломеры, возникают метаболические нарушения, приводящие к старению и формированию провоспалительного SASP-фенотипа. Стареющие клетки хрящевой ткани, синовиальной оболочки, субхондральной кости и жировой ткани взаимодействуют через паракринную сигнализацию и внеклеточные везикулы, вызывая хроническое воспаление и деградацию матрикса. Данные доклинических исследований показывают, что вмешательства, предполагающие воздействие на главные признаки старения, а именно применение сенолитиков и сеноморфиков, активация аутофагии, восстановление НАД⁺, терапия стволовыми клетками и изменение образа жизни, могут снизить бремя старения и замедлить развитие структурных нарушений, однако данных исследований на человеке по-прежнему недостаточно.
Выводы. Взгляды на OA следует пересмотреть – это возрастное системное заболевание суставов, а не просто повреждение хряща. Терапия, воздействующая на механизмы старения клеток на ранних стадиях, обладает реальным потенциалом с точки зрения изменения течения заболевания, однако для успешного внедрения в клиническую практику потребуются адаптированные к возрасту клинические стратегии и отбор пациентов по результатам анализа биомаркеров.
Ключевые слова: остеоартроз, старение, геномная нестабильность, старение хондроцитов, SASP-фенотип.
Для цитирования: Халед А. Абдель-Сатер. Остеоартроз как возрастное заболевание, поражающее различные ткани: геномная нестабильность, старение клеток и новые геротерапевтические стратегии. Клинический разбор в общей медицине. 2026; 7 (9): 91–93. DOI: 10.47407/kr2026.7.9.00935
Introduction
Osteoarthritis (OA) is the most prevalent musculoskeletal disorder and a leading cause of disability worldwide, with a rapidly increasing burden in aging populations [1]. Although genetics, obesity, sex, and joint injury contribute to risk, aging remains the strongest and most consistent determinant of OA development [2]. Epidemiological and experimental data indicate that biological aging processes – rather than mechanical wear alone – are central to disease initiation and progression [1, 3]. Modern concepts now recognize OA as a multi-tissue disorder involving cartilage, synovium, subchondral bone, and periarticular structures, all of which undergo age-related dysfunction [4].
Current OA therapies are largely palliative, focusing on pain control and functional support, with no approved disease-modifying treatments [5, 6]. This therapeutic gap reflects an incomplete targeting of upstream mechanisms. The geroscience framework proposes that conserved aging pathways drive chronic diseases, including OA [7]. Among these, cellular senescence has emerged as a key mechanism: senescent joint cells acquire a pro-inflammatory SASP that promotes matrix degradation, chronic inflammation, and secondary senescence across tissues [7–9]. While transient senescence can be beneficial, its persistent accumulation in aging joints becomes pathogenic [10].
Recognition of OA as an aging-driven condition has stimulated interest in therapies that target fundamental aging processes, including senolytics, senomorphics, and metabolic modulators [11]. This review integrates current evidence across joint compartments to clarify how genomic instability and cellular senescence orchestrate OA pathogenesis and to evaluate emerging anti-aging strategies with true disease-modifying potential.
Methods
This review followed a structured search strategy to identify evidence on aging, cellular senescence, and OA. Peer-reviewed studies published up to 2025 were retrieved from PubMed, Scopus, Web of Science, and Google Scholar using keywords including “osteoarthritis”, “aging”, “senescence”, “chondrocytes”, “SASP”, “DNA damage” and “disease-modifying therapies.”
Included were English-language studies examining age-related mechanisms in OA, biomarkers of senescence in joint tissues, and preclinical or clinical interventions targeting aging pathways. Studies focused on non-OA disorders, non–peer-reviewed sources, or reports lacking experimental or clinical data were excluded.
Findings were synthesized across molecular, preclinical, and clinical evidence to define shared biological patterns and therapeutic opportunities. This approach emphasized the multi-tissue, aging-driven nature of OA and integrated mechanistic insights with translational relevance.
Aging and Genomic Instability in Chondrocytes
DNA damage and oxidative stress. Aging and OA chondrocytes show increased DNA lesions and impaired repair capacity [12, 13]. Reactive oxygen species (ROS) accelerate telomere erosion and mitochondrial dysfunction, linking oxidative stress to senescence and matrix failure [8, 14, 15]. Persistent DNA damage activates the DNA damage response (DDR), favoring p53–p21–p16–mediated senescence rather than apoptosis, thereby promoting chronic tissue dysfunction [16–18].
Signaling pathways and organellar stress. The IKKα–NF-κB axis modulates oxidative damage responses; its suppression enhances DNA repair and limits senescence, positioning it as a therapeutic target [19, 20]. Mitochondrial DNA damage and defective mitophagy amplify ROS production, creating a self-reinforcing cycle of genomic and metabolic stress [21, 22]. Parallel lysosomal and endoplasmic reticulum stress further compromise proteostasis and cartilage integrity [21, 23].
DNA damage-induced senescence. Genomic instability drives irreversible chondrocyte senescence and acquisition of a pro-inflammatory SASP. Experimental DNA damage reproduces OA-like senescence features and SASP activation [24]. Together, these mechanisms converge on persistent senescence as the central cellular outcome that reshapes the joint microenvironment [9, 14].
Cellular senescence in the osteoarthritis joint: a multi-tissue perspective
Cartilage. Senescent chondrocytes accumulate with age and disease severity and causally drive degeneration [25, 28]. Their SASP suppresses collagen II and aggrecan synthesis while inducing matrix metalloproteinases; mTOR signaling regulates this output [29, 30]. Paracrine IL-6 signaling and EV-mediated microRNA transfer propagate senescence to neighboring cells [31–34]. Mechanical overload triggers senescence via Piezo1-mediated calcium influx and nuclear envelope stress, integrating biomechanical risk with aging biology [35–37]. Metabolic redox imbalance, circadian disruption (BMAL1 loss), and impaired FOXO–SIRT–AMPK signaling further promote chondrocyte aging [37–45].
Synovium. Senescent synovial fibroblasts accumulate through hypoxia/reoxygenation and inflammatory signaling, releasing SASP factors that intensify synovitis and cartilage damage [19, 46, 47]. Immune surveillance declines with age, enabling persistence of senescent cells through decoy receptor–mediated immune evasion [48–51].
Infrapatellar fat pad. The fat pad acts as a local senescence hub, secreting pro-inflammatory extracellular vesicles that induce chondrocyte dysfunction, paralleling systemic adipose tissue aging mechanisms [52, 53].
Subchondral bone. Senescent osteoblasts, osteocytes, and mesenchymal stromal cells disrupt bone remodeling and repair capacity; their clearance prevents age-related bone loss and OA progression [32, 54]. Stem cell exhaustion and metabolic reprogramming further accelerate sclerosis and joint degeneration [54].
Integrated mechanisms. Mechanical stress, oxidative injury, and inflammation induce senescence across joint tissues [14]. Once established, SASP signaling and extracellular vesicles create a bystander effect that spreads dysfunction [19, 55]. This self-propagating cycle represents a maladaptive “remodeling activation” program that explains disease persistence and the limited success of single-target therapies [56].
Overall, cellular senescence unifies genomic instability, metabolic failure, immune dysregulation, and biomechanical stress into a coherent model of OA pathogenesis, providing a strong rationale for senotherapeutic strategies aimed at disease modification rather than symptom control.
Anti-aging therapeutic strategies targeting osteoarthritis
Senolytic and senomorphic therapies. Senolytics aim to eliminate senescent chondrocytes, whereas senomorphics suppress SASP without inducing cell death. Dasatinib plus quercetin clears senescent cells and partially restores anabolic markers, with dasatinib providing the dominant effect [57]. Fisetin reduces chondrocyte senescence through SIRT6 pathways and slows OA progression [58]. Navitoclax shows senolytic activity but is limited by toxicity and inconsistent benefits [59]. Senomorphics such as rapamycin, resveratrol, and metformin reduce SASP and enhance autophagy, though systemic adverse effects restrict translation [14, 60, 61]. Even intra-articular hyaluronic acid exhibits senomorphic actions via SIRT1 activation and oxidative stress reduction [62].
Clinical evidence remains limited. Trials often exclude very old patients, and UBX0101 failed to meet primary endpoints in OA [39, 63, 64]. Safety concerns include transient inflammation after senescent cell clearance and drug-specific toxicities such as myelosuppression with navitoclax and dasatinib [57, 60]. Glucosamine is being reconsidered as a potential geroprotective agent through AMPK activation and autophagy enhancement, with improved delivery systems proposed to increase efficacy [65, 66]. Immunotherapeutic approaches – including CAR-T cells targeting senescent markers – represent emerging alternatives to small-molecule senolytics [67, 68].
Autophagy activation and mTOR inhibition. Enhancing autophagy offers an integrative strategy to restore cellular resilience. mTOR inhibition with rapamycin preserves chondrocyte viability, reduces synovitis, and limits cartilage loss in experimental OA [30, 69]. Activation of AMPK further supports metabolic homeostasis and suppresses senescence-associated inflammation [70]. Regenerative approaches such as autologous chondrocyte implantation and mesenchymal stem cell (MSC) therapies provide structural repair potential, with platelet-rich plasma enhancing MSC expansion and chondrogenesis [14].
Metabolic, anti-inflammaging, and regenerative strategies. Restoring NAD⁺ levels using nicotinamide riboside or nicotinamide mononucleotide improves mitochondrial function and protects cartilage in aging models, offering disease-modifying potential [71, 72]. Targeting inflammaging with metformin or low-dose cytokine inhibition can reduce SASP activity, while microRNA modulation represents an additional regulatory approach [73–75]. MSC-based therapies–particularly exosome and secretome preparations–suppress inflammation, enhance autophagy, and reduce chondrocyte senescence [76, 77]. Short-term safety appears acceptable, but long-term efficacy and durability require further study [78, 79].
Lifestyle and nutritional modulation of aging pathways in osteoarthritis
Nutrition influences OA primarily by regulating core aging mechanisms. Caloric restriction and intermittent fasting reduce senescence burden, suppress SASP mediators, and activate AMPK–sirtuin pathways while inhibiting mTOR, thereby enhancing autophagy and mitochondrial quality control in chondrocytes [23, 32, 80]. Mediterranean-style diets similarly reduce inflammation and metabolic stress, converging on pathways that delay chondrocyte senescence [81]. Caloric restriction mimetics such as resveratrol, quercetin, curcumin, metformin, and rapamycin replicate these molecular effects by suppressing NF-κB signaling and limiting cartilage catabolism [63, 82].
Physical activity functions as a systemic anti-senescence intervention. Physiological mechanical loading promotes chondrocyte autophagy, improves metabolic efficiency, and reduces inflammatory signaling, while exercise-induced myokines such as irisin inhibit NF-κB and Wnt/β-catenin pathways, protecting cartilage and subchondral bone [83, 84]. Even modest levels of regular activity are sufficient to reduce disability and preserve function in older adults with OA [85].
Circadian rhythm alignment represents an additional modifiable regulator of joint aging. Disruption of clock genes, particularly BMAL1, impairs DNA repair and autophagy and accelerates senescence in cartilage [41, 86]. Lifestyle measures that maintain circadian integrity therefore offer a practical, non-pharmacologic strategy to counteract inflammaging and slow OA progression.
Limitations, future perspectives, and conclusions
OA is a heterogeneous, aging-driven condition encompassing multiple phenotypes shaped by joint site, metabolic status, mechanical loading, and inflammatory burden. These differences lead to distinct senescence profiles and SASP signatures, limiting the universal applicability of current anti-aging strategies and complicating therapeutic translation across OA subtypes.
Clinical advancement is further constrained by the predominance of preclinical evidence, which inadequately reflects the complexity of aged human joints, comorbidities, and lifelong biomechanical stress. Additional challenges include potential off-target effects of senotherapeutics, uncertain dosing and durability, and a lack of long-term, age-stratified human trials.
Future progress depends on defining OA subtypes based on senescence burden, developing robust biomarkers for patient stratification and monitoring, and testing combination therapies that target multiple aging hallmarks. Integrating geroscience with precision medicine offers a pathway to shift OA management from symptomatic relief toward mechanism-based, disease-modifying interventions that improve joint health across the aging lifespan.
Conflict of interests. The author declares that there is not conflict of interests.
Конфликт интересов. Автор заявляет об отсутствии конфликта интересов.
Список литературы доступен на сайте журнала https://klin-razbor.ru/
The list of references is available on the journal‘s website https://klin-razbor.ru/
Information about the author
Информация об авторе
Khaled A. Abdel-Sater – MD, Department of Dental and Medical Sciences, Faculty of Dentistry, Mutah University, Al-Karak, Jordan. E-mail: Kabdelsater@mutah.edu.jo;
ORCID: 0000-0001-9357-4983
Халед А. Абдель-Сатер – д-р медицины, каф. стоматологии и медицинских наук, стоматологический факультет, Университет Мута, Эль-Карак, Иордания.
E-mail: Kabdelsater@mutah.edu.jo; ORCID: 0000-0001-9357-4983
Received: 26.01.2026
Revised: 10.02.2026
Accepted: 26.02.2026
Поступила в редакцию: 26.01.2026
Поступила после рецензирования: 10.02.2026
Принята к публикации: 26.02.2026
Список исп. литературыСкрыть список1. Hunter DJ, Bierma-Zeinstra S. Osteoarthritis. Lancet 2019;393(10182):1745-59. DOI: 10.1016/S0140-6736(19)30417-9
2. Prieto-Alhambra D, Judge A, Javaid MK et al. Incidence and risk factors for clinically diagnosed knee, hip and hand osteoarthritis. Arthritis Rheum 2014;66(4):914-22. DOI: 10.1002/art.38376
3. Del Río E. Pharmacist-Driven Chondroprotection in Osteoarthritis: A Multifaceted Approach Using Patient Education, Information Visualization, and Lifestyle Integration. Pharmacy (Basel) 2025;13(4):106. DOI: 10.3390/pharmacy13040106
4. Del Río E.A Multidimensional Definition of Pre-Osteoarthritis: Toward 21st-Century Subclinical Detection and Targeted Intervention. Int J Mol Sci 2025;26(23):11447. DOI: 10.3390/ijms262311447
5. Katz JN, Arant KR, Loeser RF. Diagnosis and treatment of hip and knee osteoarthritis. JAMA 2021;325(6):568-78. DOI: 10.1001/jama.2020.22171
6. Rodriguez-Merchan EC. The Current Role of Disease-modifying Osteoarthritis Drugs. Arch Bone Jt Surg 2023;11(1):11-22. DOI: 10.22038/ABJS.2021.56530.2807
7. Larsen PD. Geroscience: The Intersection of Basic Aging Biology, Chronic Disease, and Health. Rehabil Nurs 2019;44(4):187-8. DOI: 10.1097/RNJ.0000000000000231
8. Diekman BO, Loeser RF. Aging and the emerging role of cellular senescence in osteoarthritis. Osteoarthritis Cartilage 2024;32(4):365-71. DOI: 10.1016/j.joca.2023.11.018
9. Han Z, Wang K, Ding S, Zhang M. Cross-talk of inflammation and cellular senescence: a new insight into the occurrence and progression of osteoarthritis. Bone Res 2024;12(1):69. DOI: 10.1038/s41413-024-00375-z
10. Alum EU, Izah SC, Uti DE et al. Targeting Cellular Senescence for Healthy Aging: Advances in Senolytics and Senomorphics. Drug Des Devel Ther 2025;19:8489-522. DOI: 10.2147/DDDT.S543211
11. Di Micco R, Krizhanovsky V, Baker D, d'Adda di Fagagna F. Cellular senescence in aging: from mechanisms to therapeutic opportunities. Nat Rev Mol Cell Biol 2021;22(2):75-95. DOI: 10.1038/s41580-020-00314-w
12. Copp ME, Chubinskaya S, Bracey DN et al. Comet assay for quantification of the increased DNA damage burden in primary human chondrocytes with aging and osteoarthritis. Aging Cell 2022;21(9):e13698. DOI: 10.1111/acel.13698
13. Takada T, Kawakami A, Nakajima H et al. Potential involvement of oxidative stress in cartilage senescence and development of osteoarthritis: oxidative stress induces chondrocyte telomere instability and downregulation of chondrocyte function. Arthritis Res Ther 2008;10(4):R130. DOI: 10.1186/ar1499
14. Ramasamy TS, Yee YM, Khan IM. Chondrocyte Aging: The Molecular Determinants and Therapeutic Opportunities. Front Cell Dev Biol 2021;9:625497. DOI: 10.3389/fcell.2021.625497
15. Lu Z, Zheng C, Ren P et al. Comprehensive bioinformatics analysis reveals associations between the DNA damage response and osteoarthritis. Gerontology 2025;71(10):885-98. DOI: 10.1159/000547422
16. Mao LW, Jiang QY, Meng N et al. Sirt6 promotes DNA damage repair in osteoarthritis chondrocytes by activating the Keap1/Nrf2/HO-1 signaling pathway. Cell Cycle 2024;23(2):205-17. DOI: 10.1080/15384101.2024.2316493
17. Mijit M, Caracciolo V, Melillo A et al. Role of p53 in the Regulation of Cellular Senescence. Biomolecules 2020;10(3):420. DOI: 10.3390/biom10030420
18. Pacheco-Brousseau L, Charette M, Poitras S, Stacey D. Effectiveness of patient decision aids for total hip and knee arthroplasty decision-making: a systematic review. Osteoarthritis Cartilage 2021;29(10):1399-411. DOI: 10.1016/j.joca.2021.07.006
19. Neri S, Guidotti S, Bini C et al. Oxidative stress-induced DNA damage and repair in primary human osteoarthritis chondrocytes: focus on IKKα and the DNA Mismatch Repair System. Free Radic Biol Med 2021;166:212-25. DOI: 10.1016/j.freeradbiomed.2021.02.020
20. Neri S, Guidotti S, Panichi V et al. IKKα affects the susceptibility of primary human osteoarthritis chondrocytes to oxidative stress-induced DNA damage by tuning autophagy. Free Radic Biol Med 2024;225:726-40. DOI: 10.1016/j.freeradbiomed.2024.10.299
21. Bharath LP, Agrawal M, McCambridge G et al. Metformin Enhances Autophagy and Normalizes Mitochondrial Function to Alleviate Aging-Associated Inflammation. Cell Metab 2020;32(1):44-55.e6. DOI: 10.1016/j.cmet.2020.04.015
22. Grishko VI, Ho R, Wilson GL, Pearsall AW 4th. Diminished mitochondrial DNA integrity and repair capacity in OA chondrocytes. Osteoarthritis Cartilage 2008;17(1):107-13. DOI: 10.1016/j.joca.2008.05.009
23. Ballabio A, Bonifacino JS. Lysosomes as dynamic regulators of cell and organismal homeostasis. Nat Rev Mol Cell Biol 2020;21(2):101-18. DOI: 10.1038/s41580-019-0185-4
24. Georget M, Defois A, Guiho R et al. Development of a DNA damage-induced senescence model in osteoarthritic chondrocytes. Aging (Albany NY) 2023;15(17):8576-93. DOI: 10.18632/aging.204881
25. Jeon OH, David N, Campisi J, Elisseeff JH. Senescent cells and osteoarthritis: a painful connection. J Clin Invest 2018;128(4):1229-37. DOI: 10.1172/JCI95147
26. Wu CJ, Liu RX et al. Senescent skeletal cells and synovial cross talk in osteoarthritis. Arthritis Res Ther 2022;24(1):59. DOI: 10.1186/s13075-022-02747-4
27. Coppé JP, Desprez PY, Krtolica A, Campisi J. The senescence-associated secretory phenotype: the dark side of tumor suppression. Annu Rev Pathol 2010;5:99-118. DOI: 10.1146/annurev-pathol-121808-102144
28. Del Rey MJ, Valín Á, Usategui A et al. Senescent synovial fibroblasts accumulate prematurely in rheumatoid arthritis tissues and display an enhanced inflammatory phenotype. Immun Aging 2019;16:29. DOI: 10.1186/s12979-019-0169-4
29. Jacob J, Aggarwal A, Aggarwal A et al. Senescent chondrogenic progenitor cells derived from articular cartilage of knee osteoarthritis patients contributes to senescence-associated secretory phenotype via release of IL-6 and IL-8. Acta Histochem 2022;124(3):151867. DOI: 10.1016/j.acthis.2022.151867
30. Herranz N, Gallage S, Mellone M et al. mTOR regulates MAPKAPK2 translation to control the senescence-associated secretory phenotype. Nat Cell Biol 2015;17(9):1205-17. DOI: 10.1038/ncb3225
31. Pearson MJ, Herndler-Brandstetter D, Tariq MA et al. IL-6 secretion in osteoarthritis patients is mediated by chondrocyte-synovial fibroblast cross-talk and is enhanced by obesity. Sci Rep 2017;7(1):3451. DOI: 10.1038/s41598-017-03759-w
32. Lawrence M, Goyal A, Pathak S, Ganguly P. Cellular Senescence and Inflammaging in the Bone: Pathways, Genetics, Anti-Aging Strategies and Interventions. Int J Mol Sci 2024;25(13):7411. DOI: 10.3390/ijms25137411
33. Lehmann BD, Paine MS, Brooks AM et al. Senescence-associated exosome release from human prostate cancer cells. Cancer Res 2008;68(19):7864-71. DOI: 10.1158/0008-5472.CAN-07-6538
34. Sun Y, You Y, Wu Q et al. Senescence-targeted MicroRNA/Organoid composite hydrogel repair cartilage defect and prevention joint degeneration via improved chondrocyte homeostasis. Bioact Mater 2024;39:427-42. DOI: 10.1016/j.bioactmat.2024.05.036
35. Ren X, Li B, Xu C et al. High expression of Piezo1 induces senescence in chondrocytes through calcium ions accumulation. Biochem Biophys Res Commun 2022;607:138-45. DOI: 10.1016/j.bbrc.2022.03.119
36. Kong K, Jin M, Zhao C et al. Mechanical overloading leads to chondrocyte degeneration and senescence via Zmpste24-mediated nuclear membrane instability. iScience 2023;26(11):108119. DOI: 10.1016/j.isci.2023.108119
37. Huang K, Cai H. The role of chondrocyte senescence in osteoarthritis pathogenesis and therapeutic implications. Exp Gerontol 2025;208:112828. DOI: 10.1016/j.exger.2025.112828
38. Zhang F, Guo J, Yu S et al. Cellular senescence and metabolic reprogramming: Unraveling the intricate crosstalk in the immunosuppressive tumor microenvironment. Cancer Commun (Lond) 2024;44(9):929-66. DOI: 10.1002/cac2.12591
39. Rim YA, Nam Y, Ju JH. The Role of Chondrocyte Hypertrophy and Senescence in Osteoarthritis Initiation and Progression. Int J Mol Sci 2020;21(7):2358. DOI: 10.3390/ijms21072358
40. Bourgeois B, Madl T. Regulation of cellular senescence via the FOXO4-p53 axis. FEBS Lett 2018;592(12):2083-97. DOI: 10.1002/1873-3468.13057
41. Dudek M, Gossan N, Yang N et al. The chondrocyte clock gene Bmal1 controls cartilage homeostasis and integrity. J Clin Invest 2016;126(1):365-76. DOI: 10.1172/JCI82755
42. Nagai K, Matsushita T, Matsuzaki T et al. Depletion of SIRT6 causes cellular senescence, DNA damage, and telomere dysfunction in human chondrocytes. Osteoarthritis Cartilage 2015;23(8):1412-20. DOI: 10.1016/j.joca.2015.03.024
43. Batshon G, Elayyan J, Qiq O et al. Serum NT/CT SIRT1 ratio reflects early osteoarthritis and chondrosenescence. Ann Rheum Dis 2020;79(10):1370-80. DOI: 10.1136/annrheumdis-2020-217072
44. Loeser RF, Collins JA, Diekman BO. Aging and the pathogenesis of osteoarthritis. Nat Rev Rheumatol 2016;12(7):412-20. DOI: 10.1038/nrrheum.2016.65
45. Liu S, Zhang G, Li N et al. The Interplay of Aging and PANoptosis in Osteoarthritis Pathogenesis: Implications for Novel Therapeutic Strategies. J Inflamm Res 2025;18:1951-67. DOI: 10.2147/JIR.S489613
46. Zhang Y, Zhou S, Cai W et al. Hypoxia/reoxygenation activates the JNK pathway and accelerates synovial senescence. Mol Med Rep 2020;22(1):265-76. DOI: 10.3892/mmr.2020.11102
47. Kojima H, Inoue T, Kunimoto H, Nakajima K. IL-6-STAT3 signaling and premature senescence. JAKSTAT 2013;2(4):e25763. DOI: 10.4161/jkst.25763
48. Hall BM, Balan V, Gleiberman AS et al. p16(Ink4a) and senescence-associated β-galactosidase can be induced in macrophages as part of a reversible response to physiological stimuli. Aging (Albany NY) 2017;9(8):1867-84. DOI: 10.18632/aging.101268
49. Faust HJ, Zhang H, Han J et al. IL-17 and immunologically induced senescence regulate response to injury in osteoarthritis. J Clin Invest 2020;130(10):5493-507. DOI: 10.1172/JCI134091
50. Sagiv A, Biran A, Yon M et al. Granule exocytosis mediates immune surveillance of senescent cells. Oncogene 2013;32(15):1971-7. DOI: 10.1038/onc.2012.206
51. Yun MH, Davaapil H, Brockes JP. Recurrent turnover of senescent cells during regeneration of a complex structure. Elife 2015;4:e05505. DOI: 10.7554/eLife.05505
52. Cao Y, Ruan J, Kang J et al. Extracellular Vesicles in Infrapatellar Fat Pad from Osteoarthritis Patients Impair Cartilage Metabolism and Induce Senescence. Adv Sci (Weinh) 2024;11(3):e2303614. DOI: 10.1002/advs.202303614
53. Covarrubias AJ, Kale A, Perrone R et al. Senescent cells promote tissue NAD+ decline during aging via the activation of CD38+ macrophages. Nat Metab 2020;2(11):1265-83. DOI: 10.1038/s42255-020-00305-3
54. Farr JN, Xu M, Weivoda MM et al. Targeting cellular senescence prevents age-related bone loss in mice. Nat Med 2017;23(9):1072-9. DOI: 10.1038/nm.4385
55. Čamernik K, Mihelič A, Mihalič R et al. Increased Exhaustion of the Subchondral Bone-Derived Mesenchymal Stem/ Stromal Cells in Primary Versus Dysplastic Osteoarthritis. Stem Cell Rev Rep 2020;16(4):742-54. DOI: 10.1007/s12015-020-09964-x
56. Jeon OH, Wilson DR, Clement CC et al. Senescence cell-associated extracellular vesicles serve as osteoarthritis disease and therapeutic markers. JCI Insight 2019;4(7):e125019. DOI: 10.1172/jci.insight.125019
57. Maurer S, Kirsch V, Ruths L et al. Senolytic therapy combining Dasatinib and Quercetin restores the chondrogenic phenotype of human osteoarthritic chondrocytes by the release of pro-anabolic mediators. Aging Cell 2025;24(1):e14361. DOI: 10.1111/acel.14361
58. Yousefzadeh MJ, Zhu Y, McGowan SJ et al. Fisetin is a senotherapeutic that extends health and lifespan. EBioMedicine 2018;36:18-28. DOI: 10.1016/j.ebiom.2018.09.015
59. Chang J, Wang Y, Shao L et al. Clearance of senescent cells by ABT263 rejuvenates aged hematopoietic stem cells in mice. Nat Med 2016;22(1):78-83. DOI: 10.1038/nm.4010
60. Li W, Wang Y, Tang Y et al. Quercetin Alleviates Osteoarthritis Progression in Rats by Suppressing Inflammation and Apoptosis via Inhibition of IRAK1/NLRP3 Signaling. J Inflamm Res 2021;14:3393-403. DOI: 10.2147/JIR.S311924
61. Li J, Zhang B, Liu WX et al. Metformin limits osteoarthritis development and progression through activation of AMPK signalling. Ann Rheum Dis 2020;79(5):635-45. DOI: 10.1136/annrheumdis-2019-216713
62. Bernetti A, Agostini F, Paoloni M et al. Could Hyaluronic Acid Be Considered as a Senomorphic Agent in Knee Osteoarthritis? A Systematic Review. Biomedicines 2023;11(10):2858. DOI: 10.3390/biomedicines11102858
63. Fuggle N, Laslop A, Rizzoli R et al. Treatment of Osteoporosis and Osteoarthritis in the Oldest Old. Drugs 2025;85(3):343-60. DOI: 10.1007/s40265-024-02138-w
64. Ungprasert P, Cheungpasitporn W, Crowson CS, Matteson EL. Individual non-steroidal anti-inflammatory drugs and risk of acute kidney injury: A systematic review and meta-analysis of observational studies. Eur J Intern Med 2015;26(4):285-91. DOI: 10.1016/j.ejim.2015.03.008
65. Liu Y, Qin Z, Wang C, Jiang Z. N-acetyl-d-glucosamine-based oligosaccharides from chitin: Enzymatic production, characterization and biological activities. Carbohydr Polym 2023;315:121019. DOI: 10.1016/j.carbpol.2023.121019
66. Shakouri A, Adljouy N, Balkani S et al. Effectiveness of topical gel of medical leech (Hirudo medicinalis) saliva extract on patients with knee osteoarthritis: A randomized clinical trial. Complement Ther Clin Pract 2018;31:352-9. DOI: 10.1016/j.ctcp.2017.12.001
67. Liu Y, Zhang Z, Li T, Xu H, Zhang H. Senescence in osteoarthritis: from mechanism to potential treatment. Arthritis Res Ther 2022;24(1):174. DOI: 10.1186/s13075-022-02859-x
68. Amor C, Feucht J, Leibold J et al. Senolytic CAR T cells reverse senescence-associated pathologies. Nature 2020;583(7814):127-32. DOI: 10.1038/s41586-020-2403-9
69. Caramés B, Hasegawa A, Taniguchi N et al. Autophagy activation by rapamycin reduces severity of experimental osteoarthritis. Ann Rheum Dis 2012;71(4):575-81. DOI: 10.1136/ard.2011.155408
70. Terkeltaub R, Yang B, Lotz M, Liu-Bryan R. Chondrocyte AMP-activated protein kinase activity suppresses matrix degradation responses to proinflammatory cytokines interleukin-1β and tumor necrosis factor α. Arthritis Rheum 2011;63(7):1928-37. DOI: 10.1002/art.30333
71. Wu X, Fan X, Plan M et al. Altered nicotinamide adenine dinucleotide metabolism drives cartilage degeneration and osteoarthritis. Clin Transl Med 2025;15(11):e70513. DOI: 10.1002/ctm2.70513
72. Kiss T, Nyúl-Tóth Á, Balasubramanian P et al. Nicotinamide mononucleotide (NMN) supplementation promotes neurovascular rejuvenation in aged mice: transcriptional footprint of SIRT1 activation, mitochondrial protection, anti-inflammatory, and anti-apoptotic effects. Geroscience 2020;42(2):527-46. DOI: 10.1007/s11357-020-00165-5
73. Yan S, Dong W, Li Z et al. Metformin regulates chondrocyte senescence and proliferation through microRNA-34a/SIRT1 pathway in osteoarthritis. J Orthop Surg Res 2023;18(1):198. DOI: 10.1186/s13018-023-03571-5
74. Wojdasiewicz P, Poniatowski ŁA, Szukiewicz D. The role of inflammatory and anti-inflammatory cytokines in the pathogenesis of osteoarthritis. Mediators Inflamm 2014;2014:561459. DOI: 10.1155/2014/561459
75. Kang D, Shin J, Cho Y et al. Stress-activated miR-204 governs senescent phenotypes of chondrocytes to promote osteoarthritis development. Sci Transl Med 2019;11(486):eaar6659. DOI: 10.1126/scitranslmed.aar6659
76. Rady D, Abbass MMS, El-Rashidy AA et al. Mesenchymal Stem/Progenitor Cells: The Prospect of Human Clinical Translation. Stem Cells Int 2020;2020:8837654. DOI: 10.1155/2020/8837654
77. Luo D, Zhu H, Li S et al. Mesenchymal stem cell-derived exosomes as a promising cell-free therapy for knee osteoarthritis. Front Bioeng Biotechnol 2024;12:1309946. DOI: 10.3389/fbioe.2024.1309946
78. Kaczanowska S, Murty T, Alimadadi A et al. Immune determinants of CAR-T cell expansion in solid tumor patients receiving GD2 CAR-T cell therapy. Cancer Cell 2024;42(1):35-51.e8. DOI: 10.1016/j.ccell.2023.11.011
79. Bauer J, Biolo G, Cederholm T et al. Evidence-based recommendations for optimal dietary protein intake in older people: a position paper from the PROT-AGE Study Group. J Am Med Dir Assoc 2013;14(8):542-59. DOI: 10.1016/j.jamda.2013.05.021
80. Rizzoli R. Nutritional influence on bone: role of gut microbiota. Aging Clin Exp Res 2019;31(6):743-51. DOI: 10.1007/s40520-019-01131-8
81. Morales-Ivorra I, Romera-Baures M, Roman-Viñas B, Serra-Majem L. Osteoarthritis and the Mediterranean Diet: A Systematic Review. Nutrients 2018;10(8):1030. DOI: 10.3390/nu10081030
82. Aversa Z, White TA, Heeren AA et al. Calorie restriction reduces biomarkers of cellular senescence in humans. Aging Cell 2024;23(2):e14038. DOI: 10.1111/acel.14038
83. Petrigna L, Roggio F, Trovato B et al. How Physical Activity Affects Knee Cartilage and a Standard Intervention Procedure for an Exercise Program: A Systematic Review. Healthcare (Basel) 2022;10(10):1821. DOI: 10.3390/healthcare10101821
84. Ning K, Wang Z, Zhang XA. Exercise-induced modulation of myokine irisin in bone and cartilage tissue-Positive effects on osteoarthritis: A narrative review. Front Aging Neurosci 2022;14:934406. DOI: 10.3389/fnagi.2022.934406
85. Izquierdo M, Merchant RA, Morley JE et al. International Exercise Recommendations in Older Adults (ICFSR): Expert Consensus Guidelines. J Nutr Health Aging 2021;25(7):824-53. DOI: 10.1007/s12603-021-1665-8
86. Gossan N, Boot-Handford R, Meng QJ. Aging and osteoarthritis: a circadian rhythm connection. Biogerontology 2015;16(2):209-19. DOI: 10.1007/s10522-014-9522-3
11 ноября 2026
Количество просмотров: 50

